Introduction
============

Cerebral ischemia is a condition in which there is insufficient blood flow to the brain to meet metabolic demand. This leads to poor oxygen supply or cerebral hypoxia and results in the death of brain tissue or cerebral infarction/ischemic stroke. Cerebral ischemia is a sub-type of stroke, as are subarachnoid and intracerebral hemorrhages. Ischemic stroke remains a leading contributor to mortality rates and long-term disability worldwide ([@b1-mmr-16-06-7901]). In China, cerebral ischemia is a common cardiovascular disease and is the second most prevalent non-cancer-associated disease ([@b2-mmr-16-06-7901]). The primary pathogenesis of cerebral ischemia includes an inflammatory response, edema, hypoxia and neuronal apoptosis, which result in several motor dysfunctions, including hemiplegia and paraplegia ([@b3-mmr-16-06-7901]--[@b5-mmr-16-06-7901]). It has been identified that the prognosis of cerebral ischemia is dependent on neuron survival and improvement in terms of neurological outcome ([@b5-mmr-16-06-7901]). Accordingly, the development of innovative therapies to prevent neural damage caused by hypoxic-ischemic injury is a high priority.

The Na^+^/K^+^-ATPase (NKA) pump is an important plasma membrane protein, which comprises an α-subunit (100 kDa) and a b-subunit (55 kDa), and is situated on almost all animal cells. The primary function of NKA is the exchange of three sodium ions out of the cell for two potassium ions into the cell ([@b6-mmr-16-06-7901]). Several studies have demonstrated that, in addition to the characteristic ion transportation, NKA can transfer extracellular binding signaling into the cell through the regulation of protein tyrosine phosphorylation ([@b7-mmr-16-06-7901]--[@b9-mmr-16-06-7901]).

A polyclonal antibody has been identified that targets the DR region (Asp 897-Arg 911) of the NKA a-subunit and stimulates NKA activity ([@b10-mmr-16-06-7901],[@b11-mmr-16-06-7901]). The stimulation not only enhances heart contractility through the opening of L-type Ca^2+^ channels ([@b12-mmr-16-06-7901]), but it also induces cardioprotective effects against hypoxia/reperfusion (H/R) injury through activation of the Src/phosphoinositide 3-kinase (PI3K)/AKT/extracellular-signal regulated kinase (ERK) 1/2 pathways ([@b11-mmr-16-06-7901]).

ERK1/2 and PI3K/AKT are well-known pro-survival protein kinases important in cerebral H/R injury and have been reported to protect against transient focal cerebral H/R injury in rats by dexmedetomidine ([@b13-mmr-16-06-7901]). The present study aimed to investigate the cerebral protective effect of the DR region-specific antibody (DRSAb) and its underlying mechanism in an H/R model of U251 cells.

Materials and methods
=====================

### Animals

A total of 10 male Sprague-Dawley (SD) rats (250--300 g) were obtained from the Experimental Animal Center of Xi\'an Jiaotong University (Xi\'an, China) and housed in a standardized environment: Temperature 22°C, 50--60% humidity and 12:12 h light-dark cycle with access to laboratory rodent chow and tap water *ad libitum* under pathogen-free conditions in the Experimental Animal Center of Xi\'an Jiaotong University (Xi\'an, China). All protocols in the present study were approved by the Institutional Animal Care and Use Committees of Xi\'an Jiaotong University.

### Chemicals and reagents

The KLH-conjugated DR region peptide (897DVEDSYGQQWTYEQR911) was synthesized by GL Biochem, Ltd. (Shanghai, China). Rabbit anti-human NKAα1 subunit antibody (ATP1A1; L2C00601; 1:500), was produced by Jimianshiye (Shanghai, China), phosphorylated (P)-ERK1/2 (9106; 1:2,000), total (T)-ERK1/2 (9107; 1:1,000), P-AKT (4051; 1:1,000) and T-AKT antibodies (2920; 1:2,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Goat anti-rabbit secondary antibodies (SC-2004; 1:10,000), goat anti-rat secondary antibodies (SC-2032; 1:10,000) and goat anti-mouse secondary antibodies (SC-2005; 1:10,000) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). LY-294002 (a PI3K inhibitor) and PD-98059 (an ERK1/2 inhibitor) were purchased from EMD Millipore (Billerica, MA, USA). Complete Freund\'s adjuvant (CFA), incomplete Freund\'s adjuvant (IFA), trypan blue dye and all other reagents used in the experiments were purchased from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). All chemicals were dissolved in distilled water with the exception of PD98059 and LY-294002, which were dissolved in dimethyl sulfoxide (DMSO) at a final concentration of 0.1% (w/v).

### Preparation of DRSAb

The 10 adult male SD rats (6--8 weeks) were immunized with the KLH-conjugated DR region peptide (897DVEDSYGQQWTYEQR911) four times each week. The initial dose was 100 µg protein emulsified with CFA per rat followed by 50 µg protein emulsified with IFA per rat every week. At 5 days following the final immunization, the rats were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg; Abbott Laboratories, North Chicago, IL, USA) and all blood was collected from the heart. The blood was incubated at 37°C for 30 min and then centrifuged at 5,000 × *g* for 20 min. The sera were stored at −80°C until use.

For antibody purification, a Protein L resin column was first balanced with 10× volume of phosphate buffer (pH 7.2) and the immune sera flowed automatically through the column. The unspecific protein was washed away using washing buffer. The antibody was eluted with 0.1 M glycine (pH 3.0) and the eluted fractions were immediately adjusted to physiologic pH by adding 100 µl of 1 M phosphate (pH 8.0) to 1 ml of the eluate. The elution was monitored by measuring the absorbance at 280 nm or by a protein assay (BCA™ Protein Assay kit; Thermo Fisher Scientific, Inc., Waltham, MA, USA).

To detect the titer of the immunized sera and purified antibody, a 96-well-plate was coated with DR region peptide at a concentration of 1 µg/well. The plate was blocked with 5% BSA for 1 h at room temperature following coating with the peptide at 4°C overnight. The immunized sera and purified antibody were diluted in a two-fold serial dilution and were then incubated with the coated DR peptides at room temperature for 2 h. The bound antibody was probed with goat anti-rat immunoglobulin G (IgG)-labeled with horseradish peroxidase (SC-2032; 1:10,000; Santa Cruz Biotechnology, Inc.) for 1 h at room temperature, followed by incubation with 3,3′,5,5′-tetramethylbenzidine for 15--30 min and reading of the optical density at 405 nm. The fractions of sera were stored at −80°C for future use.

### Flow cytometric analyses

To analyze whether DRSAb was able to bind with the DR region of NKA in U251 cells, U251 cells (Cell Bank of the Chinese Academy of Sciences, Shanghai, China) were cultivated in Dulbecco\'s modified Eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% (v/v) FBS, penicillin (100 mg/ml) and streptomycin (10 mg/ml) in a humidified incubator at 37°C with 5% CO~2~ for 48 h, and then harvested and divided into three samples, each containing 1×10^5^ cells. The cells were incubated with purified DRSAb or control purified sera for 15 min at 37°C and then stained with the PE-conjugated anti-IgG heavy and light chain (H+L) antibody (BD Pharmingen, San Diego, CA, USA). The stained cells were run through a Becton Dickinson FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and the resulting data were analyzed using FlowJo software version 7.6 (Tree Star, Inc., Ashland, OR, USA).

### H/R model of U251 cells

The U251 cells were randomly divided into three groups as follows: Control group, treatment group and untreated group. In the control group, the cells were seeded into 6-well plates (1×10^5^), the culture medium was deprived of oxygen and glucose, and nitrogen-saturated D-hanks buffer solution was added, following which the culture plates were incubated for 24 h in a Tri Gas incubator (Heal Force Bio-meditech Holdings Ltd., Shanghai, China) with humidified air containing 5% CO~2~ and 94% N~2~ at 37°C to simulate hypoxia (\~1% oxygen). Subsequently, complete medium was reintroduced and the culture plates were incubated in a normal culture incubator at 37°C for 12 h to simulate re-oxygenation ([@b14-mmr-16-06-7901]). In the treatment group, all treatment procedures were the same as for H/R group; however, the cells were incubated with either control sera or different concentrations of DRSAb (0.1, 0.2, 0.3, 0.4 and 0.5 µM) during the administration of H/P. The cells in the untreated group were cultured in complete culture medium in a humidified air containing 5% CO~2~ at 37°C for 12 h without hypoxic exposure.

### Measurement of cell viability

The U251 cells were plated at a density of 1×10^4^ cells per well in 96-well plates and their viability was determined using a 3-(4,5-dimethyl thiazol-2-yl) −2,5-diphenyltetrazolium bromide (MTT) assay. The cells were treated with control purified sera or DRSAb at different concentrations and then subjected to H/R. Following H/R treatment, the cells were incubated with MTT solution (0.5 mg/ml final concentration) for 4 h at 37°C. The supernatant was then removed and the formazan crystals were dissolved in DMSO. The quantity of MTT formazan product was determined using a microplate reader (Tecan; Thermo Fisher Scientific, Inc.) at a wavelength of 560 nm.

### Annexin-V/propidium iodide (PI) staining

To examine the effect of DRSAb on apoptosis, the U251 cells treated with H/R were stained with 25 µg/ml Annexin V-fluorescein isothiocyanate and 25 µg/ml PI. The staining was performed according to the manufacturer\'s protocol. The cells were analyzed using a flow cytometer (BD FACSCalibur; BD Biosciences). Data acquisition and analysis were performed using FlowJo software version 7.6 (Tree Star, Inc.).

### SDS-PAGE and immunoblotting

SDS-PAGE and immunoblotting were performed as described previously ([@b8-mmr-16-06-7901]). The U251 cells were scraped in radio-immunoprecipitation assay lysis buffer containing protease inhibitors. Subsequently, the extracted proteins concentration was determined using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Inc.) and separated on a 10% SDS-PAGE gel (10--30 mg). The fractionated proteins were then transferred onto a nitrocellulose membrane. Specific antigens were probed with corresponding monoclonal primary antibodies, as detailed above, at 4°C overnight, followed by incubation with the horseradish peroxidase-conjugated secondary antibody (1:10,000) at room temperature for 1 h. Immunoreactivity was detected using an ECL advanced western blot detection kit (GE Healthcare Life Sciences, Chalfont, UK).

### Statistical analysis

Statistical analysis was performed using SPSS 17.0 software for Windows (SPSS, Inc., Chicago, IL, USA). All results are expressed as the mean ± standard deviation. One-way analysis of variance was used to determine the differences between each DRSAb concentration and control groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Immunologic properties of DRSAb

The titer of DRSAb was first examined. As presented in [Fig. 1A](#f1-mmr-16-06-7901){ref-type="fig"}, the titer of immunized sera was significantly higher compared with that of normal sera between dilutions of 1:100 and 1:25,600 ([Fig. 1A](#f1-mmr-16-06-7901){ref-type="fig"}). This indicated that the sera obtained were enriched with DRSAb. The SDS-PAGE data revealed two distinct H+L chain bands of the purified antibody ([Fig. 1B](#f1-mmr-16-06-7901){ref-type="fig"}). DRSAb identified NKA in the U251 cells in addition to polyclonal rabbit anti human ATP1A1 ([Fig. 1C](#f1-mmr-16-06-7901){ref-type="fig"}). The binding of DRSAb to NKA was revealed using flow cytometry. High signals were detected on the U251 cells incubated with DRSAb, but not the control sera or BSA ([Fig. 1D](#f1-mmr-16-06-7901){ref-type="fig"}).

### Effect of DRSAb on cell viability and apoptosis in H/P-treated U251 cells

The U251 cells were incubated with control sera, ATP1A1 or DRSAb at different concentrations (0.1, 0.2, 0.3, 0.4 and 0.5 µM, respectively), underwent hypoxia for 24 h and then re-oxygenation with complete medium in normal conditions for 12 h. The cells in the untreated group were cultured in complete culture medium in humidified air containing 5% CO~2~ at 37°C for 12 h without hypoxic treatment ([Fig. 2A](#f2-mmr-16-06-7901){ref-type="fig"}).

### Treatment with H/R significantly decreased cell viability

DRSAb attenuated this effect at 0.3, 0.4 and 0.5 µM ([Fig. 2B](#f2-mmr-16-06-7901){ref-type="fig"}), however, it was not attenuated in the control sera or with ATP1A1, suggesting that DRSAb may have protected the cells against H/R-induced cell injury.

The present study also investigated the effect of DRSAb on the apoptosis of U251 cell following H/R treatment by performing Annexin V/PI staining. As presented in [Fig. 2C](#f2-mmr-16-06-7901){ref-type="fig"}, the data revealed that the administration of 0.4 µM DRSAb markedly reduced the number of apoptotic cells, whereas the numbers of apoptotic cells were markedly increased in the cell cultures treated with control sera or ATP1A1.

### PI3K/AKT and ERK1/2 are involved in the protective effect of DRSAb

To investigate the involvement of PI3K/AKT and ERK1/2 in the protective effect of DRSAb, several experiments were performed. Western blot analysis demonstrated that the DRSAb-induced activation of PI3K/AKT and ERK1/2 increased depending on the concentration of DRSAb. Significant differences were identified at concentrations of 0.3, 0.4 and 0.5 µM ([Fig. 3A and B](#f3-mmr-16-06-7901){ref-type="fig"}).

In order to determine whether inhibiting the activation of PI3K/AKT and ERK1/2 eradicated the protective effect of DRSAb, the U251 cells were pre-incubated with LY-294002 (15 mM for 30 min), a selective AKT inhibitor, or PD98059 (30 µM; for 30 min), a selective pERK1/2 inhibitor, prior to treatment with DRSAb ([Fig. 4A](#f4-mmr-16-06-7901){ref-type="fig"}). It was identified that the two inhibitors eliminated the protective effects of DRSAb, which indicated that the protective effects were mediated via the PI3K/AKT and ERK1/2 pathways ([Fig. 4B](#f4-mmr-16-06-7901){ref-type="fig"}). It was also identified that LY294002 eliminated the phosphorylation of ERK1/2, whereas PD98059 did not alter the effect of DRSAb on the activation of AKT. These data suggested that PI3K/AKT was activated prior to the activation of ERK1/2 in the conditions in the present study ([Fig. 4C](#f4-mmr-16-06-7901){ref-type="fig"}).

Discussion
==========

NKA is a plasma enzyme protein responsible for the active transport or pumping of Na^+^ and K^+^ ions across the plasma membrane. Previous studies have revealed that NKA has dual functions. In addition to pumping Na^+^ and K^+^ ions across cell membranes, it relays an extracellular ouabain signal to intracellular compartments via the activation of different protein kinases ([@b15-mmr-16-06-7901]). The binding of ouabain to the signaling NKA activates the cytoplasmic tyrosine kinase, resulting in the phosphorylation of other proteins into different signaling modules. This, in turn, activates multiple protein kinase cascades, including mitogen-activated protein kinases (MAPK) and protein kinase C isozymes ([@b16-mmr-16-06-7901]). It also increases the mitochondrial production of reactive oxygen species ([@b17-mmr-16-06-7901]) and regulates intracellular calcium concentrations.

The extracellular DR region (897DVEDSYGQQ WTYEQR911) of the H7-H8 domain in the α-subunit is an important activation site of NKA, which is capable of promoting the catalytic function of the enzyme and regulating cardiac contractility ([@b10-mmr-16-06-7901]). It has been previously reported that the activation of NKA with DRSAb produces protective effects via the PI3K/AKT and ERK pathways in the heart ([@b11-mmr-16-06-7901]). It has also been reported that DRSAbs can statistically extend the survival of isolated cardiac myocytes and can protect cardiac myocytes against H/R injury by activating NKA and its subsequent signaling pathway ([@b11-mmr-16-06-7901]). Therefore, the present study hypothesized that DRSAb may have the ability to induce a protective effect on U251 cells, similar to that elicited by the activator against the DR region. In the present study, a polyclonal antibody against the NKA DR region was constructed and it was identified that DRSAb was able to bind with U251 cells. Furthermore, it was identified that incubation with DRSAb produced protective effects in U251 cells and attenuated the appostosis induced by H/R.

The ERK signaling pathway is involved in the regulation of normal cell proliferation, survival, growth and differentiation ([@b18-mmr-16-06-7901]). Studies have confirmed that the phosphorylation of ERK1/2 in cardiac myocytes and brain cells during early reperfusion serves as a protective mechanism against ischemic stress stimuli in the heart and brain ([@b11-mmr-16-06-7901],[@b19-mmr-16-06-7901]).

In addition to ERK1/2, PI3K/AKT also serves as an important signaling pathway in effecting alterations in several cellular functions in response to extracellular signals ([@b20-mmr-16-06-7901]). AKT, as a key downstream effector of PI3K, is activated in response to PI3K activation and regulates the activity of a number of targets, including kinases, transcription factors and other regulatory molecules, involved in the regulation of cell growth, proliferation and anti-apoptotic mechanisms ([@b19-mmr-16-06-7901],[@b21-mmr-16-06-7901],[@b22-mmr-16-06-7901]).

In the present study, the involvement of the PI3K/AKT and ERK pathways in the DRSAb-induced protective effect on H/R injury was examined in U251 cells, as PI3K/AKT and ERK have been reported to be essential proliferative and survival molecules in different tissues ([@b11-mmr-16-06-7901],[@b19-mmr-16-06-7901],[@b23-mmr-16-06-7901]). The present study examined the protective effect of DRSAb in the presence of LY-294002, a selective AKT inhibitor, or PD98059, a selective p42/44 MAPK inhibitor. LY-294002 and PD98059 successfully attenuated the protective effect induced by DRSAb, indicating that the protective effect of DRSAb was mediated by PI3K/AKT and ERK.

The signaling sequence of DRSAb was also examined. It was identified that the inhibition of PI3K/AKT by LY294002 attenuated the DRSAb-induced phosphorylation of ERK1/2. By contrast, the inhibition of ERK1/2 by PD98059 failed to attenuate the phosphorylation of PI3K/AKT. These data revealed that PI3K/AKT may be activated earlier than ERK1/2 in the conditions in the present study.

Taken together, the data obtained in the present study suggested that DRSAb provided cytoprotection in the H/R model through the PI3K/AKT and ERK signaling pathway.

The inhibition of PI3K/AKT and ERK contributed to the beneficial effects of DRSAb on U251 cell survival. These findings indicated that DRSAb produced important neuroprotective effects against neural injury, including ischemia in the brain. These findings suggested that there is potential for the development of DRSAb-based neuroprotectant therapies against neural damage from ischemia.
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![Immunologic properties of DRSAb. (A) Titer of immunized sera values are presented as the mean ± standard error of the mean, with error bars indicating the standard error for triplicate sample wells in the same assay (n=3). \*P\<0.05 vs. control. (B) SDS-PAGE analysis of purified antibody. Lane 1, purified antibody (5 µg); lane 2, purified antibody (10 µg). (C) NKA was detected with ATP1A1 or DRSAb in U251. Lane 1, loading sample (10 mg); lane 2, loading sample (15 mg). (D) Flow cytometric analysis of DRSAb binding on U251 cells. DRSAb, DR region-specific antibody; NKA, Na^+^/K^+^-ATPase; ATP1A1; Na^+^/K^+^ATPase α1 subunit antibody; OD, optical density.](MMR-16-06-7901-g00){#f1-mmr-16-06-7901}

![Protective effect of DRSAb in U251 cells subjected to H/R. (A) Experimental protocols. U251 cells were incubated with control sera, ATP1A1 or DRSAb at different concentrations (0.1, 0.2, 0.3, 0.4 and 0.5 µM) in culture medium deprived of oxygen and glucose, treated with hypoxia (5% CO~2~, 1% oxygen and 94% N~2~) for 24 h and then re-oxygenated with complete medium in normal conditions for 12 h. Cells in the untreated group were cultured in complete culture medium in humidified air containing 5% CO~2~ at 37°C for 12 h without hypoxic exposure. (B) Optimal concentration of DRSAb for protection was 0.4 µM (n=3). Data are presented as the mean ± standard error of the mean. \*P\<0.01 vs. control; ^\#^P\<0.05 vs. 0.2 µM. (C) Flow cytometry of Annexin-V/PI staining in U251 cells with or without DRSAb (0.4 µM) treatment. The administration of DRSAb markedly reduced the number of apoptotic cells, compared with the A277 and control sera. DRSAb, DR region-specific antibody; H/R, hypoxia/reperfusion; ATP1A1; Na^+^/K^+^ATPase α1 subunit antibody; PI, propidium iodide.](MMR-16-06-7901-g01){#f2-mmr-16-06-7901}

![PI3K/AKT and ERK1/2 are involved in the protective effect of DRSAb. Western blot analysis demonstrated that DRSAb-induced activation of (A) PI3K/AKT and (B) ERK1/2 increased depending on the concentration of DRSAb. Significant differences were identified at concentrations of 0.3, 0.4 and 0.5 µM (n=3). Data are presented as the mean ± standard error of the mean \*P\<0.05 vs. control. DRSAb, DR region-specific antibody; PI3K, phosphoinositide 3-kinase; ERK, extracellular signal-regulated kinase; P-, phosphorylated; T-, total.](MMR-16-06-7901-g02){#f3-mmr-16-06-7901}

![PI3K/AKT and ERK1/2 inhibitors attenuate the protective effect of DRSAb in U251 cells. (A) Experimental protocols. LY-294002 or PD-98059 were added 30 min prior to DRSAb and hypoxic treatment. (B) Cell viability was measured following reperfusion. Inhibition of PI3K/AKT with LY-294002 and ERK1/2 with PD-98059 eliminated the protective effect of DRSAb (n=3). (C) Western blot analysis demonstrated that the DRSAb-induced activation of PI3K/AKT and ERK1/2 were attenuated in the presence of the inhibitors (n=3). Data are presented as the mean ± standard error of the mean. \*P\<0.05 vs. control; ^\#^P\<0.05 vs. DRSAb alone. DRSAb, DR region-specific antibody; PI3K, phosphoinositide 3-kinase; ERK, extracellular signal-regulated kinase; P-, phosphorylated; OD, optical density.](MMR-16-06-7901-g03){#f4-mmr-16-06-7901}
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